How to transition from 2 mg Ativan (lorazepam) to Zoloft (sertraline)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Transitioning from Lorazepam to Sertraline

The recommended approach for transitioning from 2 mg Ativan (lorazepam) to Zoloft (sertraline) is to gradually taper lorazepam while simultaneously starting sertraline, with complete discontinuation of lorazepam over 2-4 weeks to minimize withdrawal symptoms.

Understanding the Medication Switch

Lorazepam is a benzodiazepine anxiolytic used for short-term management of anxiety and insomnia, while sertraline is an SSRI antidepressant that is a first-line treatment for generalized anxiety disorder. This transition represents a shift from a short-acting benzodiazepine to a long-term anxiety treatment option.

Rationale for the Switch

  • Lorazepam can lead to tolerance, addiction, depression, and cognitive impairment with regular use 1
  • Approximately 10% of patients may experience paradoxical agitation with benzodiazepines 1
  • SSRIs like sertraline are recommended first-line treatments for generalized anxiety disorder 2

Step-by-Step Transition Protocol

Week 1:

  1. Start sertraline at 25-50 mg once daily in the morning
  2. Continue lorazepam at current dose (2 mg) for the first 3-4 days
  3. Reduce lorazepam to 1.5 mg daily (divided into 0.5 mg three times daily) for the remainder of week 1

Week 2:

  1. Increase sertraline to 50-100 mg daily if tolerated
  2. Reduce lorazepam to 1 mg daily (0.5 mg twice daily)

Week 3:

  1. Maintain sertraline at effective dose
  2. Further reduce lorazepam to 0.5 mg daily (at bedtime)

Week 4:

  1. Continue sertraline at therapeutic dose
  2. Discontinue lorazepam completely

Important Monitoring Considerations

Potential Withdrawal Symptoms

  • Monitor for benzodiazepine withdrawal symptoms: insomnia, anxiety, irritability, tremor, headache, sensory hypersensitivity, and in severe cases, seizures 3
  • Signs and symptoms of withdrawal from benzodiazepine therapy can be delayed 1

Sertraline Initiation Effects

  • Common initial side effects include nausea, headache, dry mouth, insomnia, and diarrhea 4
  • Full therapeutic effect of sertraline may take 4-6 weeks 2

Special Considerations

Cautions

  • Never abruptly discontinue lorazepam after prolonged use due to risk of withdrawal symptoms 3
  • The required time for weaning benzodiazepines is proportional to the duration of treatment 1
  • If severe withdrawal symptoms occur, temporarily slow the taper schedule

Dosage Adjustments

  • For elderly patients or those with hepatic impairment, use lower initial doses of sertraline (25 mg) and taper lorazepam more slowly 1
  • If anxiety symptoms worsen significantly during transition, the lorazepam taper can be temporarily slowed

Alternative Approaches

If the standard approach is not tolerated:

  1. Consider a slower lorazepam taper (10-20% reduction per week) 1
  2. Divide lorazepam doses more frequently throughout the day during the taper
  3. Adjust sertraline timing to evening if daytime sedation is problematic

Common Pitfalls to Avoid

  • Tapering too quickly: This can lead to rebound anxiety and withdrawal symptoms
  • Delaying sertraline initiation: Starting sertraline before complete lorazepam discontinuation helps maintain anxiety control
  • Inadequate monitoring: Regular follow-up during the transition period is essential
  • Overlooking drug interactions: While no major interactions exist between these medications, be aware of potential additive sedative effects during the overlap period

The transition from lorazepam to sertraline represents a shift from short-term symptomatic treatment to a more appropriate long-term anxiety management strategy, with the goal of improving morbidity, mortality, and quality of life by addressing the underlying anxiety disorder while avoiding benzodiazepine dependence.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Generalized Anxiety Disorder Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Switching and stopping antidepressants.

Australian prescriber, 2016

Research

Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine.

Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.